Press Room

23 January 2014

The exponential growth of the field of antibody-drug conjugates provides plenty of business opportunities

STUTTGART, Germany I January 23, 2014 I The area of antibody-drug conjugates (ADC) is a very fertile area for business ranging from partnerships between pharma and biotech or biotech and biotech up to contract services for conducting research and manufacturing…

Read more

30 June 2013

Redistribution of market shares in the hemophilia market of recombinant coagulation factors due to new approvals and differential profiles

Time-to-market is a key success factor for novel recombinant coagulation factors from new market entrants and established marketers STUTTGART, Germany I July 1, 2013 I Last week the FDA approved Baxter’s novel recombinant factor IX (rFIX) product RIXUBIS as the…

Read more

9 May 2013

Blockbuster Biologics 2012: sales are double that of 2006 driven by strong growth of recombinant antibodies

STUTTGART, Germany | May 9, 2013 | The Business Intelligence firm La Merie Publishing released its new compilation of recombinant antibody and protein sales, this time for the year 2012. Since the first edition of this report, total sales of…

Read more

19 March 2012

The huge potential of GLP-1 receptor agonists in the diabetes market opens opportunities for technology providers and Big Pharma

Weight reduction as unique feature of GLP-1R agonists Results of cardiovascular outcomes studies eagerly awaited Demonstration of protective effect on beta cells could further boost the market potential  

Read more

24 November 2011

Blockbuster Drugs 2010: small molecules still dominating, but biologics strongly emerging

100 blockbuster drugs with combined sales of US$ 249 bln; 61% small molecule blockbusters with US$ 150 bln compared with US$ 85 bln for 31 biologic blockbusters

Read more

26 October 2011

Fierce Competition Requires Precision in Meeting the Needs of the Coagulation Factor Market

With potentially more than 20 products in the recombinant coagulation factors market within 5 to 6 years, it will be mandatory to meet the needs of a US$ 6.2 bln market in 2010 in order to gain a relevant market…

Read more

16 September 2011

Antibody-Drug Conjugates 2011 – real breakthrough still to come

Many good news (accelerated approval, impressive tumor response rates, strong pipeline fill-up, reasonable attrition rate) for the complex antibody-drug conjugate technology, but final technological, clinical and comercial validation needed

Read more

7 March 2011

Biologics Sales in 2010 exceeded US$ 100 bln

Growth drivers were therapeutic antibodies; single digit growth for most therapeutic proteins; novel anti-inflammatory antibodies continue strong growth; number of blockbuster biologics increased to 30

Read more

8 September 2010

The Product Portfolio Strategy as Decisive Force in Forming the Future Coagulation Factor Market

With over US$ 5.5 bln sales in 2009, the five recombinant products of coagulation factors VIII, IX and VIIa attracted more than 41 projects in the R&D pipeline, 12 of them already in the clinic, 7 within one year, and…

Read more

14 August 2009

Changes ahead in the coagulation factor market by new entrants and technologies

The worldwide market of recombinant and plasma derived coagulation factors grew to more than US$ 7.5 bln in 2008 and will be fundamentally challenged by over 40 projects in the R&D pipeline

Read more

11 November 2008

Trends in the diabetes drug pipeline 2008

Increasing prevalence of diabetes and an attractive market foster intense efforts in improving existing approaches and exploring new treatment modalities

Read more

28 October 2008

The future of human insulin: tailored and oral

Prevailing human insulin analogs to be followed by tailored insulin analogs and insulins with optimized drug delivery solutions

Read more